Baylor University Medical Center, Dallas, Texas, US.
Texas A&M University College of Medicine, Bryan, Texas, US.
Methodist Debakey Cardiovasc J. 2021 Nov 3;17(4):98-101. doi: 10.14797/mdcvj.576. eCollection 2021.
Patients experiencing vasoplegia, a type of distributive shock, have limited options when conventional vasopressors are not appropriate or sufficient. This is especially true for patients with cardiac dysfunction, whether after heart transplant or ventricular assist device (VAD) implantation. Angiotensin II has been used in various clinical settings for distributive shock; however, its role in patients after orthotopic heart transplant or VAD implantation is not well studied. We present two cases where angiotensin II played a vital role in correcting vasoplegia for critical cardiac patients.
患者出现血管扩张性休克（一种分布性休克）时，如果常规血管加压药不合适或效果不佳，选择有限。对于伴有心功能障碍的患者，这种情况尤其如此，无论是心脏移植后还是心室辅助装置（VAD）植入后。血管紧张素 II 已在各种临床情况下用于分布性休克；然而，其在原位心脏移植或 VAD 植入后患者中的作用尚未得到充分研究。我们介绍了两例血管扩张性休克危重心血管患者中血管紧张素 II 发挥重要作用的病例。
